VIA EDGAR
September 25, 2023
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tim Buchmiller
Re: | TransCode Therapeutics, Inc. | ||
Withdrawal of Acceleration Request and | |||
Request for Acceleration of Effectiveness | |||
Registration Statement on Form S-1, as amended | |||
File No. 333-274251 |
Dear Mr. Buchmiller,
Reference is made to the letter of TransCode Therapeutics, Inc. (the “Company”), filed as correspondence via EDGAR on September 22, 2023, in which the Company requested the acceleration of the effective time and date of Company’s Registration Statement on Form S-1, as amended (File No. 333-274251) (the “Registration Statement”) to 5:00 p.m., Eastern time, on September 26, 2023. We are no longer requesting that such Registration Statement be declared effective at this specific date and time and we hereby formally withdraw such request for acceleration.
If you have any questions regarding this request, please contact Michael Bison and Finnbarr Murphy of Goodwin Procter LLP via telephone at (617) 570-1933 and (212) 459-7257 or via e-mail (MBison@goodwinlaw.com or FMurphy@goodwinlaw.com), respectively.
Sincerely, | |
TRANSCODE THERAPEUTICS, INC. | |
/s/ Robert Michael Dudley | |
Robert Michael Dudley | |
Chief Executive Officer |
cc: | Thomas A. Fitzgerald, TransCode Therapeutics, Inc. |
Michael Bison, Goodwin Procter LLP |
Finnbarr Murphy, Goodwin Procter LLP |